ALK-Abelló Logo

ALK-Abelló

Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.

ALK | CO

Overview

Corporate Details

ISIN(s):
DK0061802139
LEI:
529900SGCREUZCZ7P020
Country:
Denmark
Address:
Bøge Alle 6-8, 2970 Hørsholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ALK-Abelló is a global pharmaceutical company specializing in the research, development, and manufacturing of allergy immunotherapy (AIT) products. A pioneer in the field for over a century, the company focuses on creating treatments that address the underlying cause of allergies, rather than merely managing symptoms. Its portfolio encompasses a range of evidence-based AIT products, including tablets, drops, and injections, as well as emergency treatments for severe allergic reactions like anaphylaxis. ALK's primary therapeutic areas are respiratory allergies, food allergies, and anaphylaxis. The company is committed to scientific innovation and expanding access to its solutions, such as needle-free adrenaline treatments, to improve the lives of people with allergies worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 09:44
M&A Activity
Danish 174.5 KB
2025-09-17 09:44
M&A Activity
Danish 10.0 KB
2025-09-17 09:44
M&A Activity
English 8.9 KB
2025-09-17 09:44
M&A Activity
English 274.6 KB
2025-08-21 07:30
Earnings Release
English 11.5 KB
2025-08-21 07:30
Interim Report
English 505.8 KB
2025-08-21 07:30
Interim Report
English 505.8 KB
2025-08-21 07:30
Earnings Release
English 12.0 KB
2025-08-12 14:45
Earnings Release
Danish 103.0 KB
2025-08-12 14:45
Earnings Release
Danish 3.7 KB
2025-08-12 14:45
Earnings Release
English 108.6 KB
2025-08-12 14:45
Earnings Release
English 3.2 KB
2025-07-18 14:01
Regulatory News Service
Danish 174.9 KB
2025-07-18 14:01
Legal Proceedings Report
English 5.2 KB
2025-07-18 14:01
Regulatory News Service
Danish 5.3 KB

Automate Your Workflow. Get a real-time feed of all ALK-Abelló filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ALK-Abelló via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Hanmi Pharm. Co., Ltd. Logo
Biopharma firm developing innovative diabetes and cancer drugs for patients and professionals.
South Korea 128940
Hansa Biopharma Logo
Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.
Sweden HNSA
HEALIOS K.K. Logo
Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.
Japan 4593
Heartseed株式会社 Logo
Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.
Japan 219A
HELLENIC DYNAMICS PLC Logo
Cultivates and supplies THC-dominant medical cannabis for the European pharmaceutical market.
United Kingdom HELD
HEMOGENYX PHARMACEUTICALS PLC Logo
Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.
United Kingdom HEMO
HEM Pharma Inc. Logo
Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.
South Korea 376270
Hemp Health Spolka Akcyjna Logo
A vertically integrated supplier of medical cannabis raw material for the Polish market.
Poland HMP
Herantis Pharma Oyj Logo
Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.
Finland HRTIS
Global manufacturer of carbapenem antibiotic APIs for regulated markets.
South Korea 106190

Talk to a Data Expert

Have a question? We'll get back to you promptly.